Why the study?
Type 2 diabetes is a leading cause of chronic kidney disease worldwide, creating a need for a comprehensive overview of pharmacological and non-pharmacological management strategies.
Answers are grounded in this paper and cite their sources.
A comprehensive, individualized approach combining pharmacological and non-pharmacological strategies is essential for preventing and managing chronic kidney disease in patients with type 2 diabetes.
Type 2 diabetes mellitus (DM2) is one of the leading causes of chronic kidney disease (CKD) worldwide. This represents a growing public health problem. It is well known the relationship between chronic kidney disease and type 2 diabetes, and one of the main objectives of the treatment is based on the prevention and education of patients and optimal pharmacological management. The prevention of CKD demands a multifaceted approach that addresses glycemic control, blood pressure management, and lipid control. These preventive measures, combined with dietary modifications, exercise, and patient education, can significantly reduce the risk of CKD development and progression. Accordingly, managing CKD in type 2 diabetes patients demands a comprehensive and individualized approach, considering these conditions’ multifaceted nature. With the right strategies and a patient-centered approach, it is possible to mitigate the impact of CKD, improve patient outcomes, and empower individuals to take control of their health in the face of these complex health challenges. This review article aims to provide a comprehensive overview of pharmacological and non-pharmacological strategies for preventing and treating chronic kidney disease in patients with type 2 diabetes and delay progression to end-stage renal disease (ESRD)
No takes yet. Share an insight, caveat, or question.
María Isabel Gómez (2023) studied Chronic Kidney Disease in Patients with Type 2 Diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: